AARTI DRUGS A long term bet

Aarti Drugs Ltd is one of the leading pharmaceutical manufacturers in India. The company is engaged manufacturing of pharmaceuticals. ADL operates in the anti-diarrhea, anti-inflammatory and anti-biotic therapeutic segments. They manufacture vitamins, anti-arthritis, anti-fungal, antibiotics, antibiotics and angiotensin converting enzyme (ACE) inhibitors in their manufacturing units located at Tarapur and Sarigam. They are having their R&D center at Tubhe, Navi Mumbai The manufacturing units of the company are GMP certified. Their products include active pharmaceutical ingredients, steroids, pharmaceutical intermediates, and specialty chemicals, such as benzene sulphonyl chloride, benzene sulphonic acid/ ammonium/ sodium salt and benzene sulphonamide. They are having one subsidiary company, namely Suyash Laboratories Ltd. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in the year 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company. During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company. During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg. During the year 2009-10, the company carried out research and development work/ process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL has sold/exported intermediates, such as Stage-I of pioglitazone and AU-% for tamsulosin. They expanded the production capacity from 25,000,000 kg to 25,716,000 kg. The company is expanding their production capacity in various products-lines to cope up the demand. They are also in the process of acquiring ISO 9002 compliance for all their units.

Result impact - 
If we see purely fundamentally then this stock has posted a result of 18 rs EPS in this quarter considering this quarter is always good for pharma companies, we will likely to see yearly EPS is around 60 Rs. Company is handsomely paying dividend rs. 10 for the whole year and posted 2 fold jump in the profits.

At the price of 377 its still cheaper and we recommend to buy at CMP for the level of 500+ in coming days.